Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 19-267

Status

Active, not recruiting

Description

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Condition

  • Solid Tumors

Interventions

  • axitinib
  • crizotinib

Phase

N/A

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Summary of Treatment Emergent Adverse Events (AEs) by Preferred Term Occurring In >20% Patients (All causality)
  • Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of axitinib
  • Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of crizotinib
  • Summary of Treatment Emergent Serious Adverse Events (SAEs) by Preferred Term (All causality)
  • Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of axitinib
  • Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of crizotinib

Enrollment

52

Study Start Date

March 7, 2003

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Pfizer

Source

Pfizer

Official title

CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS

Clinicaltrials.gov Identifier

NCT00828919

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.